These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19732174)

  • 61. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
    Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.
    Vergne L; Snoeck J; Aghokeng A; Maes B; Valea D; Delaporte E; Vandamme AM; Peeters M; Van Laethem K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):53-62. PubMed ID: 16420597
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of HIV-1 viral load on genotypic characteristics among patients failing non-nucleoside reverse trancriptase inhibitor-based first-line regimens in Northern Thailand.
    Praparattanapan J; Kotarathitithum W; Chaiwarith R; Nuntachit N; Sirisanthana T; Supparatpinyo K; Tragoolpua Y
    Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):859-66. PubMed ID: 22299468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.
    Poveda E; Anta L; Blanco JL; Pérez-Elías MJ; García F; Leal M; Ribera E; Gutiérrez F; Soriano V; de Mendoza C;
    AIDS; 2010 Jan; 24(3):469-71. PubMed ID: 20057310
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
    Munerato P; Sucupira MC; Oliveros MP; Janini LM; de Souza DF; Pereira AA; Inocencio LA; Diaz RS
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):265-73. PubMed ID: 20210652
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity.
    Hsieh SM; Pan SC; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
    AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1117-22. PubMed ID: 23594266
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
    Antinori A; Zaccarelli M; Cingolani A; Forbici F; Rizzo MG; Trotta MP; Di Giambenedetto S; Narciso P; Ammassari A; Girardi E; De Luca A; Perno CF
    AIDS Res Hum Retroviruses; 2002 Aug; 18(12):835-8. PubMed ID: 12201905
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.
    Picchio G; Vingerhoets J; Tambuyzer L; Coakley E; Haddad M; Witek J
    AIDS Res Hum Retroviruses; 2011 Dec; 27(12):1271-5. PubMed ID: 21557669
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.
    Grennan T; Walmsley S
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(6):354-63. PubMed ID: 19855100
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance.
    Liu L; May S; Richman DD; Hecht FM; Markowitz M; Daar ES; Routy JP; Margolick JB; Collier AC; Woelk CH; Little SJ; Smith DM
    AIDS; 2008 Apr; 22(7):835-9. PubMed ID: 18427201
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.
    Agneskog E; Nowak P; Källander CF; Sönnerborg A
    J Med Virol; 2013 Apr; 85(4):703-8. PubMed ID: 23364785
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Tambuyzer L; Thys K; Hoogstoel A; Nijs S; Tomaka F; Opsomer M; De Meyer S; Vingerhoets J
    Antivir Ther; 2016; 21(4):317-27. PubMed ID: 26566161
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
    Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
    J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.